sEH-IN-21

Overview

sEH-IN-21 is an orally active sEH inhibitor with IC 50 s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD).

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Epoxide Hydrolase | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > TNF Receptor

Product Information

• Catalog No.: HY-176554
• CAS No.: 3084814-46-7
• Molecular Formula: C30H40N4O5S
• Molecular Weight: 568.73
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source